GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » Asset Turnover

XAIR (Beyond Air) Asset Turnover : 0.02 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Beyond Air Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Beyond Air's Revenue for the three months ended in Sep. 2024 was $0.80 Mil. Beyond Air's Total Assets for the quarter that ended in Sep. 2024 was $49.76 Mil. Therefore, Beyond Air's Asset Turnover for the quarter that ended in Sep. 2024 was 0.02.

Asset Turnover is linked to ROE % through Du Pont Formula. Beyond Air's annualized ROE % for the quarter that ended in Sep. 2024 was -241.46%. It is also linked to ROA % through Du Pont Formula. Beyond Air's annualized ROA % for the quarter that ended in Sep. 2024 was -107.39%.


Beyond Air Asset Turnover Historical Data

The historical data trend for Beyond Air's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air Asset Turnover Chart

Beyond Air Annual Data
Trend Jun15 Jun16 Dec17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.03 - - 0.02

Beyond Air Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 0.01 0.02

Competitive Comparison of Beyond Air's Asset Turnover

For the Medical Devices subindustry, Beyond Air's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beyond Air's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Beyond Air's Asset Turnover falls into.



Beyond Air Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Beyond Air's Asset Turnover for the fiscal year that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=1.159/( (68.749+56.961)/ 2 )
=1.159/62.855
=0.02

Beyond Air's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0.798/( (46.5+53.01)/ 2 )
=0.798/49.755
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Beyond Air  (NAS:XAIR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Beyond Air's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-53.432/22.1285
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-53.432 / 3.192)*(3.192 / 49.755)*(49.755/ 22.1285)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1673.93 %*0.0642*2.2485
=ROA %*Equity Multiplier
=-107.39 %*2.2485
=-241.46 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Beyond Air's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-53.432/49.755
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-53.432 / 3.192)*(3.192 / 49.755)
=Net Margin %*Asset Turnover
=-1673.93 %*0.0642
=-107.39 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Beyond Air Asset Turnover Related Terms

Thank you for viewing the detailed overview of Beyond Air's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Beyond Air Business Description

Traded in Other Exchanges
Address
900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Executives
Robert Carey director HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Amir Avniel director, officer: President & CEO 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers officer: Chief Medical Officer C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Michael A. Gaul officer: Chief Operating Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes director C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee director C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Douglas Quinton Larson officer: Chief Financial Officer BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck officer: Chief Financial Officer C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv officer: Chief Financial Officer 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635